bupivacaine


Also found in: Dictionary, Acronyms, Wikipedia.
Related to bupivacaine: lidocaine

bupivacaine

 [bu-piv´ah-kān]
a local anesthetic, used as the hydrochloride for local infiltration, peripheral nerve block, and retrobulbar, subarachnoid, sympathetic, caudal, or epidural block.

bupivacaine

(byo͞o-pĭv′ə-kān′)
n.
A potent, long-acting anesthetic, C18H28N2, used for regional anesthesia in its hydrochloride form.

bupivacaine

A potent long-acting amide-class local anaesthetic with a 4–8 hour duration of action, which is doubled by adding adrenaline/epinephrine.

Adverse effects
• CNS toxicity—Nervousness, perioral tingling, tinnitus, tremor, dizziness, blurred vision and seizures, followed by drowsiness, loss of consciousness, respiratory depression and apnoea.
• Cardiotoxicity—Hypotension, bradycardia, arrhythmias and cardiac arrest.

bupivacaine

Marcaine® Anesthesiology A potent local anesthetic with a 4-8 hr duration of action, doubled by adding epinephrine. Cf Ropivacaine.

bupivacaine

A long-acting local anaesthetic drug often used for nerve blocks, especially in epidural anaesthesia during childbirth and for the control of postoperative pain. The drug is on the WHO official list. A brand name is Marcaine.
References in periodicals archive ?
Local Concentrations log [P.sub.(octanol/ anaesthetic utilised water)] (lipid (mg/L) partition coefficient) p[K.sub.a] Prilocaine 4,7 2.1 7 Lignocaine 4,14 2.4 7.9 Ropivacaine 4,6 2.9 8.16 Bupivacaine 4 3.4 8.1 Local Protein Volume of anaesthetic binding distribution (%) (L/kg) Prilocaine 50 0.7-4.4 Lignocaine 70 1-2 Ropivacaine 94 41-59 Bupivacaine 90 1
EPOCH 2 was a randomized, placebo- and active-controlled, double-blind, pivotal Phase 3 clinical study evaluating the efficacy and safety of locally administered HTX-011 at 300 mg/9 mg bupivacaine/meloxicam compared to placebo and the standard dose of bupivacaine solution (75 mg) for postoperative pain control following hernia repair surgery in 418 patients.
Similarly group BP patients received 100 mg Bupivacaine in 250 ml normal saline into peritoneal cavity.
The team decided to try bupivacaine because it's inexpensive and has a good duration of action, about 8 hours.
The overall safety profile of HTX-011, administered locally into the surgical site without a needle, was similar to that of the well-established safety profile of bupivacaine solution, without evidence of meloxicam-related toxicities.
Conclusion: Fixed dose of 10mg of hyperbaric 0.5% bupivacaine had similar results to height and weight-adjusted dose of bupivacaine in spinal anaesthesia for caesarean section.
"Compared with placebo, a liposomal bupivacaine incisional block at the time of cesarean delivery resulted in similar postoperative pain scores in the first 48 hours postoperatively," the authors write.
Conclusion: 0.5% hyperbaric bupivacaine was associated with better hemodynamic stability and reduced risk of bradycardia, necessity of rescue ephedrine and nausea/vomiting.
Two patients in group 3 (bupivacaine) had bradycardia intraoperatively, which was managed with intravenous atropine.
The prospective randomized study was conducted to compare the analgesic efficacy of dilute concentration of bupivacaine and ropivacaine with fentanyl.